Last reviewed · How we verify
GSK 573719 125
GSK 573719 125 is a Long-acting muscarinic antagonist (LAMA) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD). Also known as: High Dose 719.
GSK573719 is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in airway smooth muscle to promote bronchodilation.
GSK573719 is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in airway smooth muscle to promote bronchodilation. Used for Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | GSK 573719 125 |
|---|---|
| Also known as | High Dose 719 |
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting muscarinic antagonist (LAMA) |
| Target | Muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
By antagonizing muscarinic M3 receptors on airway smooth muscle, GSK573719 prevents acetylcholine-induced bronchoconstriction and promotes sustained airway relaxation. This mechanism is characteristic of anticholinergic agents used in chronic obstructive pulmonary disease (COPD) management. The long-acting formulation provides extended bronchodilatory effects with once-daily dosing.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Dry mouth
- Urinary retention
- Constipation
- Tremor
Key clinical trials
- An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A (PHASE3)
- A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK 573719 125 CI brief — competitive landscape report
- GSK 573719 125 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK 573719 125
What is GSK 573719 125?
How does GSK 573719 125 work?
What is GSK 573719 125 used for?
Who makes GSK 573719 125?
Is GSK 573719 125 also known as anything else?
What drug class is GSK 573719 125 in?
What development phase is GSK 573719 125 in?
What are the side effects of GSK 573719 125?
What does GSK 573719 125 target?
Related
- Drug class: All Long-acting muscarinic antagonist (LAMA) drugs
- Target: All drugs targeting Muscarinic M3 receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory / Pulmonology
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD)
- Also known as: High Dose 719
- Compare: GSK 573719 125 vs similar drugs
- Pricing: GSK 573719 125 cost, discount & access